Acadia Pharmaceuticals Q2 revenue rises on DAYBUE STIX demand, lifts 2026 outlook

Acadia Pharmaceuticals

04/08/2026 21:23

Overview
Neurology drugmaker's Q2 revenue rose 16% yr/yr, driven by DAYBUE and NUPLAZID sales
Q2 net income and EPS increased from prior year
Company raised full-year 2026 revenue outlook, citing higher DAYBUE guidance

Outlook
Acadia raises 2026 total revenue guidance to $1.24-$1.30 bln, up from $1.22-$1.28 bln
Company lifts 2026 DAYBUE sales guidance to $480-$510 mln, up from $460-$490 mln
Acadia expects topline Phase 2 remlifanserin results for Alzheimer's psychosis in Sep-Oct 2026

Result Drivers
DAYBUE DEMAND - Co said continued patient demand and robust uptake of DAYBUE STIX drove sales growth
NUPLAZID MOMENTUM - Co said NUPLAZID sales benefited from momentum in new-to-brand prescriptions and expanded sales force

Company press release: ID:nBw1rNSB8a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Sales
 
$307.96 mln
 
Q2 EPS
 
$0.18
 
Q2 Net Income
 
$31.50 mln
 
Q2 Operating Expenses
 
$270.12 mln
 
Q2 Pretax Profit
 
$46.47 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for ACADIA Pharmaceuticals Inc is $35.00, about 36.7% above its August 3 closing price of $25.61
The stock recently traded at 40 times the next 12-month earnings vs. a P/E of 36 three months ago

Reuters Recommended Reads
Aug 3 - Supernus, Indivior merge to strengthen neuroscience drug portfolio
Aug 4 - Harmony Biosciences Q2 WAKIX revenue beats on patient growth
Aug 4 - Pfizer Q2 results beat; raises 2026 revenue outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)